Trials / Completed
CompletedNCT00130884
Peroral Levosimendan in Chronic Heart Failure
Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at least 6 months.
Detailed description
The patients are randomised to 3 groups; higher or lower levosimendan dose group or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | levosimendan |
Timeline
- Start date
- 2005-03-01
- Completion
- 2006-03-01
- First posted
- 2005-08-16
- Last updated
- 2007-02-21
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00130884. Inclusion in this directory is not an endorsement.